Pericyte depletion results in hypoxia-associated epithelial-to-mesenchymal transition and metastasis mediated by met signaling pathway

Cancer Cell

Volumn 21, Issue 1, 2012, Pages 66-81

  Cooke, Vesselina G ^a   LeBleu, Valerie S ^a   Keskin, Doruk ^a,b   Khan, Zainab ^a   O'Connell, Joyce T ^a   Teng, Yingqi ^a   Duncan, Michael B ^a   Xie, Liang ^a   Maeda, Genta ^a   Vong, Sylvia ^a,b   Sugimoto, Hikaru ^a   Rocha, Rafael M ^c   Damascena, Aline ^c   Brentani, Ricardo R ^c   Kalluri, Raghu ^a,b,d  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c A C CAMARGO CANCER CENTER   (Brazil)

^d MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SCATTER FACTOR RECEPTOR; TRANSCRIPTION FACTOR TWIST;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER CELL; CANCER GROWTH; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; HYPOXIA; METASTASIS; MOUSE; NONHUMAN; OVERALL SURVIVAL; PERICYTE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR MICROENVIRONMENT;

EID: 84855912001     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2011.11.024     Document Type: Article

References (80)

1. Acloque H., Adams M.S., Fishwick K., Bronner-Fraser M., Nieto M.A. Epithelial-mesenchymal transitions: the importance of changing cell state in development and disease. J.Clin. Invest. 2009, 119:1438-1449.
2. Baba Y., Nosho K., Shima K., Irahara N., Chan A.T., Meyerhardt J.A., Chung D.C., Giovannucci E.L., Fuchs C.S., Ogino S. HIF1A overexpression is associated with poor prognosis in a cohort of 731 colorectal cancers. Am. J. Pathol. 2010, 176:2292-2301.
3. Bergers G., Song S. The role of pericytes in blood-vessel formation and maintenance. Neuro-oncol. 2005, 7:452-464.
4. Bergers G., Song S., Meyer-Morse N., Bergsland E., Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J.Clin. Invest. 2003, 111:1287-1295.
5. Birchmeier C., Birchmeier W., Gherardi E., Vande Woude G.F. Met, metastasis, motility and more. Nat. Rev. Mol. Cell Biol. 2003, 4:915-925.
6. Birner P., Schindl M., Obermair A., Plank C., Breitenecker G., Oberhuber G. Overexpression of hypoxia-inducible factor 1alpha is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. Cancer Res. 2000, 60:4693-4696.
7. Bos R., van der Groep P., Greijer A.E., Shvarts A., Meijer S., Pinedo H.M., Semenza G.L., van Diest P.J., van der Wall E. Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma. Cancer 2003, 97:1573-1581.
8. Brizel D.M., Sibley G.S., Prosnitz L.R., Scher R.L., Dewhirst M.W. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int. J. Radiat. Oncol. Biol. Phys. 1997, 38:285-289.
9. Carmeliet P., Jain R.K. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat. Rev. Drug Discov. 2011, 10:417-427.
10. Chen J., Imanaka N., Chen J., Griffin J.D. Hypoxia potentiates Notch signaling in breast cancer leading to decreased E-cadherin expression and increased cell migration and invasion. Br. J. Cancer 2010, 102:351-360.
11. Coussens L.M., Tinkle C.L., Hanahan D., Werb Z. MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 2000, 103:481-490.
12. Dachs G.U., Tozer G.M. Hypoxia modulated gene expression: angiogenesis, metastasis and therapeutic exploitation. Eur. J. Cancer 2000, 36(13Spec No):1649-1660.
13. Di Renzo M.F., Narsimhan R.P., Olivero M., Bretti S., Giordano S., Medico E., Gaglia P., Zara P., Comoglio P.M. Expression of the Met/HGF receptor in normal and neoplastic human tissues. Oncogene 1991, 6:1997-2003.
14. Di Renzo M.F., Olivero M., Giacomini A., Porte H., Chastre E., Mirossay L., Nordlinger B., Bretti S., Bottardi S., Giordano S., et al. Overexpression and amplification of the met/HGF receptor gene during the progression of colorectal cancer. Clin. Cancer Res. 1995, 1:147-154.
15. Dore-Duffy P. Pericytes: pluripotent cells of the blood brain barrier. Curr. Pharm. Des. 2008, 14:1581-1593.
16. Dore-Duffy P., Cleary K. Morphology and properties of pericytes. Methods Mol. Biol. 2011, 686:49-68.
17. Eberhard A., Kahlert S., Goede V., Hemmerlein B., Plate K.H., Augustin H.G. Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. Cancer Res. 2000, 60:1388-1393.
18. Ebos J.M., Lee C.R., Cruz-Munoz W., Bjarnason G.A., Christensen J.G., Kerbel R.S. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009, 15:232-239.
19. Eckerich C., Zapf S., Fillbrandt R., Loges S., Westphal M., Lamszus K. Hypoxia can induce c-Met expression in glioma cells and enhance SF/HGF-induced cell migration. Int. J. Cancer 2007, 121:276-283.
20. Erler J.T., Bennewith K.L., Nicolau M., Dornhöfer N., Kong C., Le Q.T., Chi J.T., Jeffrey S.S., Giaccia A.J. Lysyl oxidase is essential for hypoxia-induced metastasis. Nature 2006, 440:1222-1226.
21. Folkman J. Tumor angiogenesis: therapeutic implications. N.Engl. J.Med. 1971, 285:1182-1186.
22. Folkman J. Tumor angiogenesis. Adv. Cancer Res. 1974, 19:331-358.
23. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1995, 1:27-31.
24. Garcia S., Dalès J.P., Charafe-Jauffret E., Carpentier-Meunier S., Andrac-Meyer L., Jacquemier J., Andonian C., Lavaut M.N., Allasia C., Bonnier P., Charpin C. Poor prognosis in breast carcinomas correlates with increased expression of targetable CD146 and c-Met and with proteomic basal-like phenotype. Hum. Pathol. 2007, 38:830-841.
25. Gupta G.P., Massagué J. Cancer metastasis: building a framework. Cell 2006, 127:679-695.
26. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
27. Hara S., Nakashiro K., Klosek S.K., Ishikawa T., Shintani S., Hamakawa H. Hypoxia enhances c-Met/HGF receptor expression and signaling by activating HIF-1alpha in human salivary gland cancer cells. Oral Oncol. 2006, 42:593-598.
28. Harris A.L. Hypoxia-a key regulatory factor in tumour growth. Nat. Rev. Cancer 2002, 2:38-47.
29. Hayashi M., Sakata M., Takeda T., Tahara M., Yamamoto T., Okamoto Y., Minekawa R., Isobe A., Ohmichi M., Tasaka K., Murata Y. Up-regulation of c-met protooncogene product expression through hypoxia-inducible factor-1alpha is involved in trophoblast invasion under low-oxygen tension. Endocrinology 2005, 146:4682-4689.
30. Hellström M., Kalén M., Lindahl P., Abramsson A., Betsholtz C. Role of PDGF-B and PDGFR-beta in recruitment of vascular smooth muscle cells and pericytes during embryonic blood vessel formation in the mouse. Development 1999, 126:3047-3055.
31. Huang F.J., You W.K., Bonaldo P., Seyfried T.N., Pasquale E.B., Stallcup W.B. Pericyte deficiencies lead to aberrant tumor vascularizaton in the brain of the NG2 null mouse. Dev. Biol. 2010, 344:1035-1046.
32. Jain R.K. Transport of molecules in the tumor interstitium: a review. Cancer Res. 1987, 47:3039-3051.
33. Jain R.K. Molecular regulation of vessel maturation. Nat. Med. 2003, 9:685-693.
34. Joyce J.A. Therapeutic targeting of the tumor microenvironment. Cancer Cell 2005, 7:513-520.
35. Kalluri R. EMT: when epithelial cells decide to become mesenchymal-like cells. J.Clin. Invest. 2009, 119:1417-1419.
36. Kalluri R., Weinberg R.A. The basics of epithelial-mesenchymal transition. J.Clin. Invest. 2009, 119:1420-1428.
37. Kenworthy P., Dowrick P., Baillie-Johnson H., McCann B., Tsubouchi H., Arakaki N., Daikuhara Y., Warn R.M. The presence of scatter factor in patients with metastatic spread to the pleura. Br. J. Cancer 1992, 66:243-247.
38. Kim J.A., Tran N.D., Li Z., Yang F., Zhou W., Fisher M.J. Brain endothelial hemostasis regulation by pericytes. J.Cereb. Blood Flow Metab. 2006, 26:209-217.
39. Koukourakis M.I., Giatromanolaki A., Sivridis E., Simopoulos C., Turley H., Talks K., Gatter K.C., Harris A.L. Hypoxia-inducible factor (HIF1A and HIF2A), angiogenesis, and chemoradiotherapy outcome of squamous cell head-and-neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 2002, 53:1192-1202.
40. Liebner S., Fischmann A., Rascher G., Duffner F., Grote E.H., Kalbacher H., Wolburg H. Claudin-1 and claudin-5 expression and tight junction morphology are altered in blood vessels of human glioblastoma multiforme. Acta Neuropathol. 2000, 100:323-331.
41. Lu C., Kamat A.A., Lin Y.G., Merritt W.M., Landen C.N., Kim T.J., Spannuth W., Arumugam T., Han L.Y., Jennings N.B., et al. Dual targeting of endothelial cells and pericytes in antivascular therapy for ovarian carcinoma. Clin. Cancer Res. 2007, 13:4209-4217.
42. Lu C., Shahzad M.M., Moreno-Smith M., Lin Y.G., Jennings N.B., Allen J.K., Landen C.N., Mangala L.S., Armaiz-Pena G.N., Schmandt R., et al. Targeting pericytes with a PDGF-B aptamer in human ovarian carcinoma models. Cancer Biol. Ther. 2010, 9:176-182.
43. Mendel D.B., Laird A.D., Xin X., Louie S.G., Christensen J.G., Li G., Schreck R.E., Abrams T.J., Ngai T.J., Lee L.B., et al. Invivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin. Cancer Res. 2003, 9:327-337.
44. Motzer R.J., Hutson T.E., Tomczak P., Michaelson M.D., Bukowski R.M., Rixe O., Oudard S., Negrier S., Szczylik C., Kim S.T., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N.Engl. J.Med. 2007, 356:115-124.
45. Muñoz-Nájar U.M., Neurath K.M., Vumbaca F., Claffey K.P. Hypoxia stimulates breast carcinoma cell invasion through MT1-MMP and MMP-2 activation. Oncogene 2006, 25:2379-2392.
46. Natali P.G., Nicotra M.R., Di Renzo M.F., Prat M., Bigotti A., Cavaliere R., Comoglio P.M. Expression of the c-Met/HGF receptor in human melanocytic neoplasms: demonstration of the relationship to malignant melanoma tumour progression. Br. J. Cancer 1993, 68:746-750.
47. Newman P.J. The role of PECAM-1 in vascular cell biology. Ann. N Y Acad. Sci. 1994, 714:165-174.
48. O'Keeffe M.B., Devlin A.H., Burns A.J., Gardiner T.A., Logan I.D., Hirst D.G., McKeown S.R. Investigation of pericytes, hypoxia, and vascularity in bladder tumors: association with clinical outcomes. Oncol. Res. 2008, 17:93-101.
49. Ozerdem U. Targeting of pericytes diminishes neovascularization and lymphangiogenesis in prostate cancer. Prostate 2006, 66:294-304.
50. Ozerdem U. Targeting pericytes diminishes neovascularization in orthotopic uveal melanoma in nerve/glial antigen 2 proteoglycan knockout mouse. Ophthalmic Res. 2006, 38:251-254.
51. Ozerdem U., Freeman W.R., Bartsch D.U., Clark T.M. A simple noncontact wide-angle fundus photography procedure for clinical and research use. Retina 2001, 21:189-190.
52. Ozerdem U., Grako K.A., Dahlin-Huppe K., Monosov E., Stallcup W.B. NG2 proteoglycan is expressed exclusively by mural cells during vascular morphogenesis. Dev. Dyn. 2001, 222:218-227.
53. Ozerdem U., Monosov E., Stallcup W.B. NG2 proteoglycan expression by pericytes in pathological microvasculature. Microvasc. Res. 2002, 63:129-134.
54. Pàez-Ribes M., Allen E., Hudock J., Takeda T., Okuyama H., Viñals F., Inoue M., Bergers G., Hanahan D., Casanovas O. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009, 15:220-231.
55. Pennacchietti S., Michieli P., Galluzzo M., Mazzone M., Giordano S., Comoglio P.M. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 2003, 3:347-361.
56. Pietras K., Hanahan D. A multitargeted, metronomic, and maximum-tolerated dose " chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. J.Clin. Oncol. 2005, 23:939-952.
57. Pouysségur J., Dayan F., Mazure N.M. Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 2006, 441:437-443.
58. Qian F., Engst S., Yamaguchi K., Yu P., Won K.A., Mock L., Lou T., Tan J., Li C., Tam D., et al. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases. Cancer Res. 2009, 69:8009-8016.
59. Raza A., Franklin M.J., Dudek A.Z. Pericytes and vessel maturation during tumor angiogenesis and metastasis. Am. J. Hematol. 2010, 85:593-598.
60. Rofstad E.K. Microenvironment-induced cancer metastasis. Int. J.Radiat. Biol. 2000, 76:589-605.
61. Schlingemann R.O., Rietveld F.J., de Waal R.M., Ferrone S., Ruiter D.J. Expression of the high molecular weight melanoma-associated antigen by pericytes during angiogenesis in tumors and in healing wounds. Am. J.Pathol. 1990, 136:1393-1405.
62. Semenza G.L. Angiogenesis in ischemic and neoplastic disorders. Annu. Rev. Med. 2003, 54:17-28.
63. Sennino B., Falcón B.L., McCauley D., Le T., McCauley T., Kurz J.C., Haskell A., Epstein D.M., McDonald D.M. Sequential loss of tumor vessel pericytes and endothelial cells after inhibition of platelet-derived growth factor B by selective aptamer AX102. Cancer Res. 2007, 67:7358-7367.
64. Stefansson I.M., Salvesen H.B., Akslen L.A. Vascular proliferation is important for clinical progress of endometrial cancer. Cancer Res. 2006, 66:3303-3309.
65. Stohrer M., Boucher Y., Stangassinger M., Jain R.K. Oncotic pressure in solid tumors is elevated. Cancer Res. 2000, 60:4251-4255.
66. Sugimoto H., Mundel T.M., Kieran M.W., Kalluri R. Identification of fibroblast heterogeneity in the tumor microenvironment. Cancer Biol. Ther. 2006, 5:1640-1646.
67. Sun S., Ning X., Zhang Y., Lu Y., Nie Y., Han S., Liu L., Du R., Xia L., He L., Fan D. Hypoxia-inducible factor-1alpha induces Twist expression in tubular epithelial cells subjected to hypoxia, leading to epithelial-to-mesenchymal transition. Kidney Int. 2009, 75:1278-1287.
68. Thiery J.P. [Epithelial-mesenchymal transitions in cancer onset and progression]. Bull. Acad. Natl. Med. 2009, 193:1969-1978. discussion, 1978-1969.
69. Thiery J.P., Acloque H., Huang R.Y., Nieto M.A. Epithelial-mesenchymal transitions in development and disease. Cell 2009, 139:871-890.
70. Tong R.T., Boucher Y., Kozin S.V., Winkler F., Hicklin D.J., Jain R.K. Vascular normalization by vascular endothelial growth factor receptor2blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res. 2004, 64:3731-3736.
71. Trimboli A.J., Fukino K., de Bruin A., Wei G., Shen L., Tanner S.M., Creasap N., Rosol T.J., Robinson M.L., Eng C., et al. Direct evidence for epithelial-mesenchymal transitions in breast cancer. Cancer Res. 2008, 68:937-945.
72. Vleugel M.M., Greijer A.E., Shvarts A., van der Groep P., van Berkel M., Aarbodem Y., van Tinteren H., Harris A.L., van Diest P.J., van der Wall E. Differential prognostic impact of hypoxia induced and diffuseHIF-1alpha expression in invasive breast cancer. J.Clin. Pathol. 2005, 58:172-177.
73. Xian X., Håkansson J., Ståhlberg A., Lindblom P., Betsholtz C., Gerhardt H., Semb H. Pericytes limit tumor cell metastasis. J.Clin. Invest. 2006, 116:642-651.
74. Xie K., Huang S. Regulation of cancer metastasis by stress pathways. Clin. Exp. Metastasis 2003, 20:31-43.
75. Xie L., Duncan M.B., Pahler J., Sugimoto H., Martino M., Lively J., Mundel T., Soubasakos M., Rubin K., Takeda T., et al. Counterbalancing angiogenic regulatory factors control the rate of cancer progression and survival in a stage-specific manner. Proc. Natl. Acad. Sci. USA 2011, 108:9939-9944.
76. Yang J., Mani S.A., Donaher J.L., Ramaswamy S., Itzykson R.A., Come C., Savagner P., Gitelman I., Richardson A., Weinberg R.A. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 2004, 117:927-939.
77. Yang M.H., Wu M.Z., Chiou S.H., Chen P.M., Chang S.Y., Liu C.J., Teng S.C., Wu K.J. Direct regulation of TWIST by HIF-1alpha promotes metastasis. Nat. Cell Biol. 2008, 10:295-305.
78. Yonenaga Y., Mori A., Onodera H., Yasuda S., Oe H., Fujimoto A., Tachibana T., Imamura M. Absence of smooth muscle actin-positive pericyte coverage of tumor vessels correlates with hematogenous metastasis and prognosis of colorectal cancer patients. Oncology 2005, 69:159-166.
79. You W.K., Sennino B., Williamson C.W., Falcón B., Hashizume H., Yao L.C., Aftab D.T., McDonald D.M. VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer. Cancer Res. 2011, 71:4758-4768.
80. Zou H.Y., Li Q., Lee J.H., Arango M.E., McDonnell S.R., Yamazaki S., Koudriakova T.B., Alton G., Cui J.J., Kung P.P., et al. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res. 2007, 67:4408-4417.